Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Background Infection with coronavirus SARS-CoV-2, causing COVID-19 disease, leads to
inflammation and a prothrombotic state. Objective This rapid systematic review aims to …

Background COVID-19 is a respiratory disease that results in a prothrombotic state
manifesting as thrombotic, microthrombotic and thromboembolic events. As a result, several …

Objectives To determine the effect of therapeutic anticoagulation, with low molecular weight
heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to …

Background: Preliminary data highlights the importance of anticoagulation therapy in the
prevention and treatment of thromboembolism in SARS CoV-2 infection. There is insufficient …

Purpose As no reported randomized control trials (RCTs) directly compare the three
administration doses of anticoagulants (prophylactic dose, treatment dose, and no …

Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …

Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with
increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has …

Although primarily affecting the respiratory system, COVID-19 causes multiple organ
damage. One of its grave consequences is a prothrombotic state that manifests as …

A proportion of people infected with SARS-CoV-2 develop moderate or severe COVID-19,
with an increased risk of thromboembolic complications. The inflammatory response to …